Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in VOR held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 5.7M | $104.4M | 0.0% | 9.508% | 2.51% |
| 2 | FMR LLC | 4.9M | $90.8M | +220.3% | 8.266% | 0.00% |
| 3 | FCPM III SERVICES B.V. | 4.1M | $75.8M | 0.0% | 6.900% | 10.10% |
| 4 | BlackRock, Inc. | 3.5M | $63.8M | +336.4% | 5.812% | 0.00% |
| 5 | Venrock Adviser, LLC | 3.0M | $56.0M | 0.0% | 5.098% | 1.70% |
| 6 | STATE STREET CORP | 2.6M | $48.2M | +133.9% | 4.385% | 0.00% |
| 7 | Frazier Life Sciences Management, L.P. | 2.5M | $46.8M | 0.0% | 4.263% | 1.02% |
| 8 | RA CAPITAL MANAGEMENT, L.P. | 2.4M | $44.2M | -55.6% | 4.026% | 0.38% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $38.4M | +45.4% | 3.493% | 0.00% |
| 10 | Caligan Partners LP | 1.9M | $35.4M | 0.0% | 3.226% | 1.67% |
| 11 | Paradigm Biocapital Advisors LP | 1.8M | $32.2M | 0.0% | 2.933% | 0.60% |
| 12 | GREAT POINT PARTNERS LLC | 1.7M | $31.3M | -2.9% | 2.849% | 5.91% |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1.1M | $19.6M | +210.1% | 1.781% | 0.00% |
| 14 | NEXTBio Capital Management LP | 889K | $16.4M | -11.1% | 1.490% | 7.53% |
| 15 | Nantahala Capital Management, LLC | 845K | $15.6M | β | 1.416% | 0.26% |
| 16 | ADAR1 Capital Management, LLC | 681K | $12.5M | β | 1.141% | 0.57% |
| 17 | Logos Global Management LP | 650K | $12.0M | -13.3% | 1.089% | 0.52% |
| 18 | Rosalind Advisors, Inc. | 649K | $11.9M | -7.3% | 1.087% | 4.44% |
| 19 | NAN FUNG TRINITY (HK) Ltd | 647K | $11.9M | β | 1.083% | 1.18% |
| 20 | BRAIDWELL LP | 573K | $10.6M | +22.8% | 0.961% | 0.39% |
| 21 | BOOTHBAY FUND MANAGEMENT, LLC | 559K | $10.3M | +0.5% | 0.936% | 0.14% |
| 22 | UBS Group AG | 493K | $9.1M | +1.0% | 0.827% | 0.00% |
| 23 | MILLENNIUM MANAGEMENT LLC | 428K | $7.9M | +65.5% | 0.717% | 0.00% |
| 24 | SPHERA FUNDS MANAGEMENT LTD. | 416K | $7.7M | +29.4% | 0.698% | 1.00% |
| 25 | Woodline Partners LP | 380K | $7.0M | β | 0.636% | 0.02% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in VOR β a direct measure of their conviction.
Filings activity in VOR during Q2 2026, grouped by how each filer changed its position.
4 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 102 | +28% | 81.40% | +12.98 pp | $893M | +24% |
| Q1 2026 | 80 | +43% | 68.42% | +18.59 pp | $720M | +105% |
| Q4 2025 | 56 | +40% | 49.83% | +30.84 pp | $350M | 29% |
| Q3 2025 | 40 | β | 18.99% | β | $496M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.
Quick answers to the most common questions about buying VOR stock.
Based on Q2 2026 13F filings, institutional ownership of Vor Biopharma Inc. stands at 81.4%, held across 102 reporting institutions.
TCG Crossover Management, LLC is the largest reported institutional holder of VOR, with approximately 5,673,078 shares worth $0.10B as of Q2 2026.
Yes β 1 widely-followed marquee investor appear among the top 25 institutional holders of VOR, including MILLENNIUM MANAGEMENT LLC.
Our composite Smart Money Score for VOR is 65 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
38 institutions opened new positions in VOR during Q2 2026, while 17 fully exited. 45 added to existing positions and 18 trimmed.
VOR institutional ownership rose by 12.98 percentage points quarter-over-quarter, with a net change of +22 holders.
The top 10 institutions account for 67.6% of all reported 13F value in VOR, and the top 25 account for 91.8%.
Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.